Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: A review

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 4, 2011, Pages 433-439

  Monedero, Ignacio ^a,b   Caminero, J A ^a,c  

^a MDR TB Unit   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

FDC; Fixed dose combinations; MDR; Multidrug resistance; TB; Tuberculosis

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIMATAZID; RIMSTAR; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTHROPATHY; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; MONOTHERAPY; MUSCLE DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; RECURRENCE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 79952812559     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.09.0439     Document Type: Review

References (41)

1. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251. (Pubitemid 39311345)
2. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15. (Pubitemid 28108937)
3. Caminero Luna J A. A tuberculosis guide for specialist physicians. Paris, France: International Union Against Tuberculosis and Lung Disease, 2004.
4. Pillai G, Fourie P B, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316; discussion S17-S21.
5. Laserson K F, Kenyon A S, Kenyon T A, Layloff T, Binkin N J. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001; 5: 448-454. (Pubitemid 32397569)
6. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2004; 276: 41-49. (Pubitemid 38542986)
7. Panchagnula R, Agrawal S, Kaur K J, Singh I, Kaul C L. Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol. Int J Tuberc Lung Dis 2000; 4: 1169-1172. (Pubitemid 32046296)
8. Agrawal S, Kaur K J, Singh I, Bhade S R, Kaul C L, Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2002; 233: 169-177. (Pubitemid 34230429)
9. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63: 535-553. (Pubitemid 36384620)
10. Bhutani H, Mariappan T T, Singh S. The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions. Int J Tuberc Lung Dis 2004; 8: 1073-1080. (Pubitemid 39201252)
11. Ashokraj Y, Kohli G, Kaul C L, Panchagnula R. Quality control of anti-tuberculosis FDC formulations in the global market: Part II. Accelerated stability studies. Int J Tuberc Lung Dis 2005; 9: 1266-1272.
12. Gabriels G A, McIlleron H, Smith P J, Folb PI, Fourie P B. Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs. Int J Tuberc Lung Dis 2007; 11: 181-188. (Pubitemid 46219282)
13. Chaulet P. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S353-S357; discussion S381-S387.
14. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79: 61-68. (Pubitemid 32154097)
15. Geiter L J, O'Brien R J, Combs D L, Snider D E Jr. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987; 68 (Suppl): S41-S46.
16. Bellabas M, Khaled S, Aït-Khaled N, Boulahbal F, Chaulet P. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis]. Rev Mal Respir 1989; 6: 59-64. [French]
17. Agounitestane D, Chiheb M, Khaled S, Aït-Khaled N, Boulahbal F, Chaulet P. [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]. Rev Mal Respir 1990; 7: 209-213. [French]
18. Chaulet P, Boulahbal F. [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiotherapie de la Tuberculose]. Tubercle Lung Dis 1995; 76: 407-412. [French]
19. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1989; 140: 1618-1622.
20. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1991; 143 (4 Pt 1): 700-706.
21. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1991; 143 (4 Pt 1): 707-712.
22. Teo S K. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3: 126-132. (Pubitemid 29151815)
23. Zhu L, Yan B, Ma W. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi 1998; 21: 645-647. [Chinese]
24. Su W J, Perng R P. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002; 6: 1029-1032.
25. Gravendeel J M, Asapa A S, Becx-Bleumink M, Vrakking H A. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb) 2003; 83: 183-186. (Pubitemid 36683570)
26. Suryanto A A, van den Broek J, Hatta M, de Soldenhoff R, van der Werf M J. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis 2008; 12: 174-179.
27. Moulding T S, Le H Q, Rikleen D, Davidson P. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 2004; 8: 743-748. (Pubitemid 38747151)
28. International Union Against Tuberculosis and Lung Disease. Multicentre trial for the evaluation of a fixed dose combined tablet for the treatment of pulmonary tuberculosis. Paris, France: The Union, 2007. http://clinicaltrials. gov/show/NCT00216333 Accessed January 2011.
29. Bartacek A, Schutt D, Panosch B, Borek M. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
30. Lienhardt C, Cook S, Yorke-Edwards V, et al. Investigation of the safety and efficacy of a 4-FDC for the treatment of tuberculosis (Study C): methods and preliminary results of the 12 month follow-up of patients. 39th Union World Conference on Lung Health, Paris, France: 2008. Int J Tuberc Lung Dis 2008; 12 (Suppl 2): S46. [Symposium Abstract]
31. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/publications/global-report/2009/en/index.html Accessed February 2010.
32. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 3. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
33. Uplekar M, Lönnroth K. MDR and XDR - the price of delaying engagement with all care providers for control of TB and TB/HIV. Trop Med Int Health 2007; 12: 473-474.
34. Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 2001; 358: 912-916.
35. Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis (Edinb) 2003; 83: 156-164. (Pubitemid 36683566)
36. Matiru R. Marking up the medicines. Geneva, Switzerland: Global Drug Facility, 2008: pp 1-2. http://www.stoptb.org/assets/documents/gdf/whatis/ Marking%20up%20the%20Medicine.pdf Accessed January 2011.
37. Moulding T. Failure to mention fixed-dose drug combinations in the ATS/CDC/IDSA tuberculosis control statement. Am J Respir Crit Care Med 2006; 173: 684; author reply: 684-685.
38. Hinderaker S G, Ysykeeva J, Veen J, Enarson D A. Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan. Int J Tuberc Lung Dis 2009; 13: 1560-1562.
39. Norval P Y, Blomberg B, Kitler M E, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S292-S300; discussion S317-S321.
40. Stop TB Partnership. TB facts and figures. Geneva, Switzerland: WHO, 2009. http: //www.stoptb.org/gdf/whatis/facts-and-figures. asp Accessed July 2010.
41. Laing R O, McGoldrick K M. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 2000; 4 (Suppl 2): S194-S207. (Pubitemid 32046282)